Community curated by people like you

Pharmaceutical earnings stories

Jul 15, 2026

Johnson & Johnson beats earnings estimates on strength of Tremfya and Darzalex

Johnson & Johnson exceeded Wall Street estimates for second-quarter sales and profit, driven by strong demand for immunology drug Tremfya and cancer treatment Darzalex, offsetting erosion in other product lines.

Jul 15, 2026·1 source

00

Top claims

▪Sales of the immunology drug Tremfya jumped 72.5% to $2 billion, while sales of blood cancer treatment Darzalex were $4.2 billion
▪The growth in newer drugs like Tremfya is helping to offset falling revenue from Stelara, which has lost its patent protection
▪The pharmaceutical unit generated $16.38 billion in quarterly sales, ahead of the $16.1 billion average estimate from analysts

Subtopics

Cancer treatment1 Pharma1 Wall Street1

Related timelines

Congress

Payments

Trump administration

US health policy & drug pricing

AI Data Center Gold Rush